In the meantime, JP Morgan downgraded its Organon & Co [OGN] rating to an Underweight from a a Neutral in a research note published on September 06, 2024; the price target was increased to $20 from $18. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early November from “a Buy” to “a Neutral”. Barclays began covering OGN with “an Overweight” recommendation on September 21, 2023. Raymond James started covering the stock on March 16, 2023. It rated OGN as “an Outperform”.
Price Performance Review of OGN
On Monday, Organon & Co [NYSE:OGN] saw its stock jump 4.26% to $12.72. Over the last five days, the stock has gained 19.66%. Organon & Co shares have fallen nearly -14.75% since the year began. Nevertheless, the stocks have fallen -32.01% over the past one year. While a 52-week high of $23.10 was reached on 02/13/25, a 52-week low of $10.45 was recorded on 04/21/25. SMA at 50 days reached $14.02, while 200 days put it at $16.91.
Levels Of Support And Resistance For OGN Stock
The 24-hour chart illustrates a support level at 12.38, which if violated will result in even more drops to 12.05. On the upside, there is a resistance level at 12.93. A further resistance level may holdings at 13.15. The Relative Strength Index (RSI) on the 14-day chart is 50.19, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.80, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 10.98%. Stochastics %K at 64.93% indicates the stock is a holding.
How much short interest is there in Organon & Co?
A steep rise in short interest was recorded in Organon & Co stocks on 2025-04-15, dropping by -0.93 million shares to a total of 17.43 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 18.36 million shares. There was a decline of -5.33%, which implies that there is a negative sentiment for the stock.
